1. Generics Bulletin
  2. >>Business
  3. >>Deals

ANI Pharma Looks to Buy A Platform For Its Push Into Injectables

 
• By Aidan Fry

Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.

Injection
ANI Pharmaceuticals is looking to acquire assets to support its push into the US injectables arena • Source: Shutterstock

US generics player ANI Pharmaceuticals is looking to buy manufacturing assets to support its expansion from the solid and liquid oral-dose sector into the injectables arena. Having recently acquired four development-stage generic injectables from Coeptis Pharmaceuticals, the Minnesota-based firm currently has a pipeline of six injectable drugs.

“With the money we have available to us as we move into the injectable platform, we will be looking for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By Dave Wallace

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By Dean Rudge

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.